<DOC>
	<DOCNO>NCT01281514</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin pegylated liposomal doxorubicin hydrochloride ( PLD ) work different way stop growth tumor cell , either kill cell stop dividing . Everolimus may stop growth tumor cell block enzymes need cell growth . Giving carboplatin PLD together everolimus may kill tumor cell . PURPOSE : This phase I trial study side effect best dose everolimus give together carboplatin PLD treat patient relapsed ovarian epithelial , fallopian tube , peritoneal cavity cancer</brief_summary>
	<brief_title>Carboplatin , Pegylated Liposomal Doxorubicin Hydrochloride , Everolimus Treating Patients With Relapsed Ovarian Epithelial , Fallopian Tube , Peritoneal Cavity Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) RAD001 ( everolimus ) combination carboplatin PLD . SECONDARY OBJECTIVES : I . Determine safety/tolerability three drug combination carboplatin , PLD RAD001 ( everolimus ) . II . Determine preliminary analysis anti-tumor activity regimen patient recurrent ovarian , fallopian tube primary peritoneal cancer . OUTLINE : This dose-escalation study everolimus . Patients receive carboplatin intravenously ( IV ) PLD IV day 1 everolimus orally ( PO ) daily day 1-28 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 2 month 1 year .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically confirm epithelial ovarian , fallopian tube , primary peritoneal carcinoma Patients must exactly one prior platinum/taxanebased chemotherapeutic regimen management primary disease , must first relapse ; first relapse must occur &gt; = six month completion frontline platinumbased therapy ; ( time measure last platinum dose ; example , patient receive biologic chemotherapeutic agent completion platinumbased therapy part upfront therapy would eligible base time last dose platinum chemotherapy ; situation , patient must least four week last dose biologic agent ) ; relapse base rise cancer antigen ( CA ) 125 alone ; must radiographic evidence recurrent disease Measurable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) v1.1 criterion nonmeasurable disease symptomatic malignant pleural effusion malignant ascites ; site disease pleural effusion , cytologic confirmation recurrence obtain Patients must major surgery radiation therapy within 14 day start study treatment All acute toxicity prior therapy exception alopecia must resolve = &lt; grade 1 Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Absolute neutrophil count ( ANC ) &gt; = 1500 Platelets &gt; = 100K Serum total bilirubin = &lt; 1.5x upper limit normal ( ULN ) Serum transaminase ( aspartate aminotransferase [ AST ] /serum glutamic oxaloacetic transaminase [ SGOT ] , alanine aminotransferase [ ALT ] /serum glutamic pyruvic transaminase [ SGPT ] ) activity = &lt; 2.5 x ULN International normalize ratio ( INR ) = &lt; 1.5 partial thromboplastin time ( PTT ) = &lt; 1.5 x ULN patient treat therapeutic anticoagulation ; therapeutic prophylactic anticoagulation allow patient stable dose low molecular weight ( LMW ) heparin &gt; 2 week time randomization ; subject therapeutic prophylactic anticoagulation include warfarin PTT INR determine Investigator ; prophylactic use anticoagulant maintain patency vascular access device also allow ) Serum creatinine = &lt; 2.0 Creatinine clearance &gt; 60 ml/min Left ventricular ejection fraction ( LVEF ) &gt; low limit normal ( LLN ) multi gate acquisition scan ( MUGA ) Ability understand willingness sign write informed consent document Ability take oral medication Fasting serum cholesterol &lt; 300 mg/dL triglyceride &lt; 2.5 x ULN ; Note : case one threshold exceed , patient include initiation appropriate lipid lower medication repeat analysis , level fall within parameter Able willing comply test treatment outline protocol Patients one prior chemotherapy regimen management primary disease Patients receive prior mammalian target rapamycin ( mTOR ) inhibitor Chronic treatment systemic steroid immunosuppressive agent ; Note : topical inhaled steroid allow Uncontrolled brain leptomeningeal metastasis , include continue require glucocorticoid brain leptomeningeal metastases Other malignancy = &lt; 3 year prior registration except adequately treat carcinoma cervix basal squamous carcinoma skin Other concurrent severe and/or uncontrolled medical disease could compromise participation study ; example include , limited : uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN ; uncontrolled hypertension , great 150/100 spite antihypertensive therapy ; active ( acute chronic ) uncontrolled severe infection ; unstable angina pectoris , symptomatic congestive heart failure ( New York Heart Association Class III IV ) ; ventricular arrhythmia , active ischemic heart disease , myocardial infarction within six month ; liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis Known history human immunodeficiency virus ( HIV ) seropositivity patient increase risk lethal infection treat marrowsuppressive therapy potential pharmacokinetic interaction antiretroviral therapy investigational agent Known history Hepatitis B C patient may risk disease reactivation treat chemotherapy and/or investigational agent Patients receive immunization attenuate live vaccine = &lt; 7 day study entry study period Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 ( i.e . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection sufficient impair absorption drug ) Patients clinical symptom gastrointestinal obstruction require parenteral hydration/nutrition Patients active bleed diathesis Women pregnant breastfeeding , woman able conceive unwilling practice effective method birth control ; ( woman childbearing potential must negative urine serum pregnancy test within = &lt; 7 day prior administration RAD001 ) ; oral , implantable injectable contraceptive may affect cytochrome P450 interaction therefore consider effective study History noncompliance medical regimen Patients know hypersensitivity study agent Patients unwilling unable comply outline protocol Patients psychiatric illness social situation would limit compliance study requirement</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>